Clinical trials: Ulcer, Gastric
Osteoarthritis, Peptic Ulcer
A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin
The purpose of this study is to compare the gastroduodenal ulceration rate, gastrointestinal complication rate and non-steroidal anti-inflammatory drug-associated dyspepsia between lansoprazole, naproxen and celecoxib, taken once…
- Trial name
- NCT00175032
- Testing
- Lansoprazole and naproxen and aspirin, Celecoxib and aspirin
- Volunteers
- 1,045 people
- Sponsor
- Takeda
Gastric Adenoma, Early Gastric Cancer
The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer
Endoscopic submucosal dissection (ESD) is an advanced technique that enables en bloc resection of superficial tumors in the gastrointestinal tract.
- Trial name
- NCT02243618
- Testing
- Polaprezinc, Rebamipide
- Where
- South Korea
- Volunteers
- 153 people
- Sponsor
- Yonsei University
Cirrhosis, Chronic Liver Disease
The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient
The aim of this study is to assess the role of portal hypertension of peptic ulcer disease in liver cirrhosis and chronic hepatitis.
- Trial name
- NCT01944878
- Where
- South Korea
- Volunteers
- 455 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Esophagitis, Reflux
Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis
STU-Na belongs to the proton pump inhibitors (PPI), a group of drugs that reduce gastric acidity. PPI are used to treat acid related diseases like erosive or ulcerative esophagitis.
- Trial name
- NCT00282555
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- 17 sites in Canada
- Volunteers
- 450 people
- Sponsor
- STEBA France